{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:08:05Z","timestamp":1789373285292,"version":"build-2803163510"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CAD"],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>introduction:<\/jats:title>\n                    <jats:p>The recent outbreak of COVID-19 has emerged as a major global health threat, with rapid transmission and high mortality rates. Despite extensive efforts, the availability of effective antiviral drugs and vaccines remains limited, highlighting the urgent need for collaborative research to identify novel therapeutic candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>materials and methods:<\/jats:title>\n                    <jats:p>\u2022 Methods\nStructure\u2013activity relationship (SAR) analysis was employed to design novel derivatives from shikimic acid. The synthesized virtual compounds were subjected to molecular docking using the Schrodinger suite and Discovery Studio to assess their binding affinity toward the SARS-CoV-2 main protease. In-silico ADMET screening was performed to evaluate pharmacokinetic and toxicity profiles. The most promising compound was further analyzed through molecular dynamics (MD) simulation for 100 ns to investigate the stability and dynamic behaviour of the protein\u2013ligand complex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>results:<\/jats:title>\n                    <jats:p>\u2022 Results\nDocking studies using the Schr\u00f6dinger suite revealed that compounds T2 (\u22126.84 kcal\/mol) and T1 (\u22126.75 kcal\/mol) exhibited higher binding affinity toward SARS-CoV-2 compared with hydroxychloroquine (\u22125.47 kcal\/mol). Key interactions involved residues SER46, MET49, HIE41, GLN189, ARG188, ASP187, MET165, HIE164, THR24, THR25, LEU27, ASN142, and GLY143. Redocking of the co-crystal ligand validated the docking protocol, yielding an RMSD of 0.000 \u00c5. Discovery Studio results supported these findings, and ADMET predictions indicated favourable pharmacokinetic properties. A 100-ns MD simulation of the T1\u2013protein complex further confirmed its stable binding behaviour..<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>discussion:<\/jats:title>\n                    <jats:p>Docking, ADMET, and MD results demonstrate that shikimic acid derivatives, particularly T1, exhibit superior binding, stability, and drug-likeness, highlighting their potential as SARS-CoV-2 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>conclusion:<\/jats:title>\n                    <jats:p>\u2022 Conclusion\nThe in silico findings suggest that the shikimic acid\u2013derived compounds, T1 may possess promising inhibitory potential against SARS-CoV-2, supported by strong binding affinity, favourable ADMET profiles, and stable protein\u2013ligand interactions. These compounds warrant further experimental validation as potential COVID-19 therapeutic candidates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115734099485678260825093451","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:46:51Z","timestamp":1789372011000},"source":"Crossref","is-referenced-by-count":0,"title":["Computational Identification of Shikimic Acid Derivatives as Potential SARS-CoV-2 Inhibitors: An In Silico Approach"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1562-8956","authenticated-orcid":true,"given":"Hardha","family":"Balachandran","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-4777","authenticated-orcid":true,"given":"Kaviarasan","family":"Lakshmanan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmacy, Satyabhama Institute of Science and Technology, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipen","family":"Purohit","sequence":"additional","affiliation":[{"name":"Analytical Development &amp; Control, Navinta LLC,1499 Lower Ferry Road, Ewing, NJ08618, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Stanley Vineth","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7464","authenticated-orcid":true,"given":"Gowramma","family":"Byran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-4316","authenticated-orcid":true,"given":"Kalirajan","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education &amp; Research, Ooty, Nilgiris, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734099485678260825093451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258144\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734099485678260825093451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:46:51Z","timestamp":1789372011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258144\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734099485678260825093451","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,8]]}}}